WJOG5108L_2A: WJOG5108L, figure 2A

WJOG5108L_2AR Documentation

WJOG5108L, figure 2A

Description

Kaplan-Meier digitized data from WJOG5108L, figure 2A (PMID 27022112). A reported sample size of 561 for a primary endpoint of PFS in lung cancer.

Usage

WJOG5108L_2A

Format

A data frame of 559 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (erlotinib, gefitinib)

Source

Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016; 34: 3248–57.

Examples

summary(WJOG5108L_2A)

kmplot(WJOG5108L_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.